Liggett and his research team suggest that therapeutics targeting PLCb may have substantial benefit in the treatment of asthma, particularly when chronic beta-agonist use is prescribed. Shore and Drazen suggest that it is possible that this is "just the tip of the iceberg" and that "understanding the panoply of beta2AR-mediated events in airway smooth muscle might lead to the design of new agonists that avoid negative effects of beta2AR activation while enhancing events that lead to relaxation".
TITLE: Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox
Stephen B. Liggett
University Of Cincinnati, Cincinnati, Ohio, USA.
Phone: (513) 558-4831
Fax 1: (513) 558-0835
View the PDF of this article at: https://www.the-jci.org/press/18193.pdf
Beta-agonists and asthma: too much of a good thing?
Harvard School of Public Health, Boston, Massachusetts, USA.
Phone 1: (617) 432-0199
Fax 1: (617) 432-3468
Contact: Brooke Grindlinger
Journal of Clinical Investigation